The 6-Min Walk Test in Pulmonary Arterial Hypertension: Only for Bad News?

Deboeck, Gaël

doi:10.1159/000377708

Cited by 1 publication

(2 citation statements)

References 14 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 6MXD is indispensable for dynamic observation and decisionmaking on further treatment tactics For citation : Снижение толерантности к физической нагрузкеглавный клинический симптом ЛГ. Дистанция в тесте шестиминутной ходьбы (6МХ) -простой, доступный и воспроизводимый критерий переносимости физической нагрузки, отражающий способность к увеличению сердечного выброса и пиковое потребление кислорода [21][22][23][24]. Согласно современным рекомендациям [1][2][3] достижение дистанции 6МХ>380-440 м -одна из целей терапии ЛГ.…”

Section: динамика дистанции шестиминутной ходьбы как показатель эффек...unclassified

“…Наконец, как замечают G. Deboeck и соавт. [24], корреляция динамики дистанции 6МХ с клиническим течением ЛГ (при отсутствии «исцеляющего» эффекта) может не выявляться из-за статистических погрешностей.…”

Section: комбинированные первичные конечные точки рки легочных вазоди...unclassified

See 1 more Smart Citation

Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators

Шмальц

2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Pulmonary hypertension is a severe and often rapidly progressive disease with a fatal outcome. Approved specific therapy with five classes of drugs – prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators and prostacyclin receptor agonists has significantly improved the prognosis of patients. An accessible and reproducible criterion of exercise tolerance – a distance walked in six-minute walk test (6MXD) – occupies one of the central places among the performance indicators (clinical, echocardiographic and hemodynamic) of specific pulmonary vasodilators. Reflecting the clinical severity of pulmonary hypertension and, according to some data, its long-term prognosis, the dynamics of 6MXD is an integral component of the combined primary endpoints of randomized controlled trials. In the CHEST-2019 recommendations, the dynamics of the 6MXD was used to standardize the randomized controlled trials. The 6MXD is indispensable for dynamic observation and decisionmaking on further treatment tactics

show abstract

Section: динамика дистанции шестиминутной ходьбы как показатель эффек...unclassified

Section: комбинированные первичные конечные точки рки легочных вазоди...unclassified

Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators

Шмальц

2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

The 6-Min Walk Test in Pulmonary Arterial Hypertension: Only for Bad News?

Cited by 1 publication

References 14 publications

Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators

Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators

Contact Info

Product

Resources

About